Trial Profile
Safety and efficacy of afatinib monotherapy in patients with EGFR-mutant non-small cell lung cancer: A retrospective cohort study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2017
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Feb 2017 New trial record